No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study

Li Ting Kao, Chao Yuan Huang, Herng Ching Lin, Chi Ming Chu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To date, the actual relationship between antimuscarinics for overactive bladder (OAB) syndrome and the subsequent risk of a fracture remains unclear. The aim of this retrospective cohort study was to demonstrate the association between antimuscarinics for OAB and fractures using a large population-based data set. Data used in this study were taken from the Taiwan Longitudinal Health Insurance Database 2005. We identified 2927 OAB patients who received antimuscarinics as the study cohort and 11 708 matched OAB patients who did not receive antimuscarinics as the comparison cohort. Each individual was tracked for a 3-year period to define those who received a diagnosis of a fracture. Stratified Cox proportional hazard regression analyses were conducted to estimate the association between antimuscarinics for OAB and a subsequent fracture. Results revealed that the incidence rate of fracture per 100 person-years within the 3-year follow-up period were 3.01 (95% confidence interval [CI], 2.65-3.40) for OAB patients who received antimuscarinics and 2.77 (95%CI, 2.60-2.95) for those OAB patients who did not receive antimuscarinics. The adjusted hazard ratio (HR) for a subsequent fracture for OAB patients who received antimuscarinics was 1.11 (95%CI, 0.97-1.28) compared with those OAB patients who did not receive antimuscarinics. Consequently, we concluded that antimuscarinics for OAB was not significantly predictive of fracture.

Original languageEnglish
JournalJournal of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Overactive Urinary Bladder
Muscarinic Antagonists
Cohort Studies
Retrospective Studies
Confidence Intervals
Health Insurance
Taiwan
Regression Analysis
Databases

Keywords

  • Antimuscarinics
  • Bladder
  • Fracture
  • Muscarinic receptor antagonist
  • Overactive bladder syndrome

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{08a07bd739d1414c89210c695ff6d0b4,
title = "No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study",
abstract = "To date, the actual relationship between antimuscarinics for overactive bladder (OAB) syndrome and the subsequent risk of a fracture remains unclear. The aim of this retrospective cohort study was to demonstrate the association between antimuscarinics for OAB and fractures using a large population-based data set. Data used in this study were taken from the Taiwan Longitudinal Health Insurance Database 2005. We identified 2927 OAB patients who received antimuscarinics as the study cohort and 11 708 matched OAB patients who did not receive antimuscarinics as the comparison cohort. Each individual was tracked for a 3-year period to define those who received a diagnosis of a fracture. Stratified Cox proportional hazard regression analyses were conducted to estimate the association between antimuscarinics for OAB and a subsequent fracture. Results revealed that the incidence rate of fracture per 100 person-years within the 3-year follow-up period were 3.01 (95{\%} confidence interval [CI], 2.65-3.40) for OAB patients who received antimuscarinics and 2.77 (95{\%}CI, 2.60-2.95) for those OAB patients who did not receive antimuscarinics. The adjusted hazard ratio (HR) for a subsequent fracture for OAB patients who received antimuscarinics was 1.11 (95{\%}CI, 0.97-1.28) compared with those OAB patients who did not receive antimuscarinics. Consequently, we concluded that antimuscarinics for OAB was not significantly predictive of fracture.",
keywords = "Antimuscarinics, Bladder, Fracture, Muscarinic receptor antagonist, Overactive bladder syndrome",
author = "Kao, {Li Ting} and Huang, {Chao Yuan} and Lin, {Herng Ching} and Chu, {Chi Ming}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcph.1067",
language = "English",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome

T2 - A Retrospective Cohort Study

AU - Kao, Li Ting

AU - Huang, Chao Yuan

AU - Lin, Herng Ching

AU - Chu, Chi Ming

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To date, the actual relationship between antimuscarinics for overactive bladder (OAB) syndrome and the subsequent risk of a fracture remains unclear. The aim of this retrospective cohort study was to demonstrate the association between antimuscarinics for OAB and fractures using a large population-based data set. Data used in this study were taken from the Taiwan Longitudinal Health Insurance Database 2005. We identified 2927 OAB patients who received antimuscarinics as the study cohort and 11 708 matched OAB patients who did not receive antimuscarinics as the comparison cohort. Each individual was tracked for a 3-year period to define those who received a diagnosis of a fracture. Stratified Cox proportional hazard regression analyses were conducted to estimate the association between antimuscarinics for OAB and a subsequent fracture. Results revealed that the incidence rate of fracture per 100 person-years within the 3-year follow-up period were 3.01 (95% confidence interval [CI], 2.65-3.40) for OAB patients who received antimuscarinics and 2.77 (95%CI, 2.60-2.95) for those OAB patients who did not receive antimuscarinics. The adjusted hazard ratio (HR) for a subsequent fracture for OAB patients who received antimuscarinics was 1.11 (95%CI, 0.97-1.28) compared with those OAB patients who did not receive antimuscarinics. Consequently, we concluded that antimuscarinics for OAB was not significantly predictive of fracture.

AB - To date, the actual relationship between antimuscarinics for overactive bladder (OAB) syndrome and the subsequent risk of a fracture remains unclear. The aim of this retrospective cohort study was to demonstrate the association between antimuscarinics for OAB and fractures using a large population-based data set. Data used in this study were taken from the Taiwan Longitudinal Health Insurance Database 2005. We identified 2927 OAB patients who received antimuscarinics as the study cohort and 11 708 matched OAB patients who did not receive antimuscarinics as the comparison cohort. Each individual was tracked for a 3-year period to define those who received a diagnosis of a fracture. Stratified Cox proportional hazard regression analyses were conducted to estimate the association between antimuscarinics for OAB and a subsequent fracture. Results revealed that the incidence rate of fracture per 100 person-years within the 3-year follow-up period were 3.01 (95% confidence interval [CI], 2.65-3.40) for OAB patients who received antimuscarinics and 2.77 (95%CI, 2.60-2.95) for those OAB patients who did not receive antimuscarinics. The adjusted hazard ratio (HR) for a subsequent fracture for OAB patients who received antimuscarinics was 1.11 (95%CI, 0.97-1.28) compared with those OAB patients who did not receive antimuscarinics. Consequently, we concluded that antimuscarinics for OAB was not significantly predictive of fracture.

KW - Antimuscarinics

KW - Bladder

KW - Fracture

KW - Muscarinic receptor antagonist

KW - Overactive bladder syndrome

UR - http://www.scopus.com/inward/record.url?scp=85040315303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040315303&partnerID=8YFLogxK

U2 - 10.1002/jcph.1067

DO - 10.1002/jcph.1067

M3 - Article

AN - SCOPUS:85040315303

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -